Evidence map›Paper›PMID 32694237›Full record

ArticleAging2020

miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.

Zhi-Chao Wang, Yan Li, Ke-Liang Wang, Lu Wang, Bo-Sen You, Dan-Feng Zhao, Zhong-Qing Liu, Rui-Zhe Fang, Jia-Qi Wang, Wei Zhang and 2 more

RetractedOpen access · greenAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Zhi-Chao WangHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Yan LiDepartment of Anesthesia, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Ke-Liang WangHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Lu WangHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Bo-Sen YouHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Dan-Feng ZhaoHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Zhong-Qing LiuHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Rui-Zhe FangHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Jia-Qi WangHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Wei ZhangHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Jin-Ming ZhangHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Wan-Hai XuHeilongjiang Key Laboratory of Scientific Research in Urology, The Forth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Fourth Affiliated Hospital of Harbin Medical University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whether serine protease inhibitor Kazal type 1 (SPINK1) being associated with enzalutamide (Enz) resistance and metastasis of castration-resistant prostate cancer (CRPC) has not been clear. SPINK1 promoted Enz resistance by upregulating Androgen receptor splicing variant 7 (ARv7), and enhanced the invasion/migration of Enz-resistant cells via ERK/p38/ MMP9 signaling. Furthermore, miR-5089-5p suppressed SPINK1 mRNA through direct binding to its 3'UTR, and reversed its pro-proliferative and pro-metastatic effects. Mice bearing SPINK1-knockdown Enz-resistant PCa tumors showed significantly longer survival compared with those bearing wild-type tumors, while treatment with miR-5089-5p inhibitor abrogated the protective effects of SPINK1 knockdown. Taken together, SPINK1 can be used as a biomarker of resistance to Enz, and the miR-5089-5p/SPINK1/MAPK/MMP9 axis is a suitable therapeutic target against Enz-resistant and metastatic CRPC.Methods: The expression of SPINK1 in Enz-resistant prostate cancer (PCa) cell lines was detected through next-generation sequencing data and metastatic PCa patients. In vivo and in vitro experiments were performed to investigate the role of SPINK1 in Enz-resistance and metastasis.

Indexed as

Alternative SplicingAnimalsAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmHumansMaleMAP Kinase Signaling SystemMatrix Metalloproteinase 9MiceMice, Inbred BALB CMicroRNAsMitogen-Activated Protein KinasesNeoplasm MetastasisNitrilesPhenylthiohydantoinAntineoplastic AgentsBenzamidesenzalutamideMatrix Metalloproteinase 9MicroRNAsMitogen-Activated Protein KinasesMMP9 protein, humanNitrilesPhenylthiohydantoinReceptors, AndrogenSPINK1 protein, humanTrypsin Inhibitor, Kazal Pancreaticcastration resistant prostate cancerenzalutamide resistancemetastasismiR-5089-5pSPINK1

Identifiers

PMID32694237
PMCPMC7425449
OpenAlexW4206240529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.